Awards and Honors:

1.Member of the Standing Committee of the 12th All-China Youth Federation, Chairman of the Medical and Health Sector;

2.Deputy Chairman of the General Surgery Group, Military Health Care Committee of the PLA;

3.Deputy Group Leader of the Hepatology Group, General Surgery Committee of the Chinese Medical Association;

4.Review Expert for the Rising Star Program of the former General Logistics Department of the PLA;

5.Academic Leader of the PLA 122 Talent Project.

Research Projects:

1.2016/12–2021/12, Principal Investigator, Project of Jiangsu Provincial Department of Science and Technology, Construction of South China Genetic Resources Research Center, Chinese Academy of Sciences (BM2016034), 30 million RMB, Completed.

2.2022/10, Project Leader, Major Technological Breakthrough Project of Shenzhen Science and Technology Innovation Commission, R&D and Application of Key Technical Platform for Point-of-Care Testing (POCT) (Project No. Chong2022D013) (Shenzhen Sci-Tech Innovation Grant [2022] No. 50), 3 million RMB, Ongoing.

3.2023/12, Principal Investigator, Major Key Technology Project of Shenzhen Science and Technology Innovation Commission, R&D of Plasma Tumor Conformal Ablation System (Shenzhen Sci-Tech Innovation Grant [2023] No. 92), 1.5 million RMB, Ongoing.

4.2024/1, Core Principal Investigator, Research Project of Shenzhen Medical Academy, Immune Editing Mechanism of Plasma on Tumor Microenvironment and Its Clinical Application (Clinical Medicine Special Project No. C231011), 2 million RMB, Ongoing.

5.2022/10, Core Principal Investigator, Horizontal Project commissioned by Miaoshun Biotechnology Co., Ltd., Collection of Peripheral Blood Leukocytes for New Drug Discovery and Preclinical Research of Immunotargeted Drugs for Various Tumors, 3 million RMB. Project ongoing.

Publications:

[1] Xu, Z., Wang, Y, Han, J., Xu, Q., Ren, J., Xu, J., Wang, Y, Chai, Z., 2018. Noninvasive Multimodal Imaging of Osteosarcoma and Lymph Nodes Using a 99mTc-Labeled Biomineralization Nanoprobe. Anal Chem 90, 4529–4534.

[2] Chen, Q., Xia, M., Tang, M., Liu, M., Yan, D., Chen, W., Xu, S., Xu, Z., Chen, Y.H., Zhang, G., Wan, X., Zhu, W.-G., 2025. DR5 CAR-NK cells demonstrate superior scalability and potent antitumor activity with favorable safety. Mol Ther 33, 6063–6081.

[3] Ibrahim, A., Mohamady Farouk Abdalsalam, N., Liang, Z., Kashaf Tariq, H., Li, R., O Afolabi, L., Rabiu, L., Chen, X., Xu, S.#, Xu, Z.#, Wan, X.#, Yan, D.#, 2025. MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy. Cancer Gene Ther 32, 371–392.

[4] Khan, I., Fang, Q., Fei, C., Wang, Z., Chen, Z, Chen, G., Xu, Z.#, Xu, S#., Chen, Z#, Cold atmospheric plasma-mediated tumor microenvironment remodeling for cancer treatment. BMEMat, e70041.

[5] Ling, Y., Hu, M., Zeng, Y., Mao, Q., Deng, W., Ben, Y.#, Andrews, C.B., Xu, Z.#, Wong, M.H., Zheng, C., 2025. Characterizing human exposure to multi-class antibiotics through urine biomonitoring in a Chinese population. Emerging Contaminants 11, 100587.

[6] Niu, X., Zhang, P., Liu, Z., Tang, Y., Xu, S., Wan, X., Xu, Z.#, Zhang, G.#, 2025. Lentinan enhances CAR-T cell potency in solid tumors by optimizing T cell differentiation. Frontiers in Immunology.

[7] Rabiu, L., Zhang, P., Liu, Z., Tang, Y., Gidado, K.I., Ibrahim, A., Saliu, M.A., Tariq, H.K., Wan, X., Xu, S.#, Xu, Z.#, Zhang, G.#, 2025. TIPE2 deficiency amplifies inflammation and immune dysregulation in MASH through modulating hepatic lipid metabolism and immune cell function. Inflamm Res 74, 65.